Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
27 Apr 2020
Long-term use of brivaracetam as an adjunctive treatment is well tolerated and effective in patients with focal seizures or primary generalized seizures, as shown in a study.
01 Apr 2019
Perampanel is safe and effective for treating refractory focal seizures in both Asian and non‐Asian populations, a study has found.
Elvira Manzano, 20 Jun 2018
A higher proportion of patients with systemic lupus erythematosus (SLE) experienced improvements in joint and skin symptoms with baricitinib 4 mg once daily vs placebo in a phase II randomized, double-blind, global study.

Pasireotide LAR trumps pegvisomant in reducing vertebral fracture risk in SRL-resistant acromegaly

11 Feb 2020

The risk of incident vertebral fractures (VFs) is lower among acromegaly patients with biochemically active disease treated with pasireotide LAR (Pasi) compared with those on pegvisomant (PegV), reports a recent study, which also confirms that the presence of pre-existent VFs is the main cause of incident VFs.

The investigators conducted a longitudinal retrospective international study to examine the incidence of radiological VFs in 55 patients with acromegaly who are resistant to first-generation somatostatin receptor ligands (SRL).

Twenty-three (41.8 percent) patients presented with prevalent VFs at study entry. The proportion of patients achieving biochemical acromegaly control was comparable between the two treatment groups (PegV vs Pasi: 66.7 percent vs 66.7 percent).

During follow-up, 16 patients (29.1 percent) were diagnosed with incident VFs. The occurrence of incident VFs correlated with prevalent VFs (p=0.002), persistence of active acromegaly (p=0.01) and higher value of insulin-life growth factor 1 (IGF-1) during follow-up (p=0.03).

Among patients with active disease at last visit, the occurrence of incident VFs was less frequent in those treated with Pasi compared with PegV (25 percent vs 77.8 percent; p=0.04), independently of the IGF-1 values (p=0.90). Among those who reached biochemical control, more patients in the PegV compared with the Pasi group had incident VFs (22.7 percent vs 12.5 percent; p=0.40).

Furthermore, the main determinant for incident VFs among both treatment groups was the presence of pre-existent VFs.

“Additional studies on larger populations and with longer follow-up are needed to confirm our data and disclose the mechanisms underlying our findings,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
27 Apr 2020
Long-term use of brivaracetam as an adjunctive treatment is well tolerated and effective in patients with focal seizures or primary generalized seizures, as shown in a study.
01 Apr 2019
Perampanel is safe and effective for treating refractory focal seizures in both Asian and non‐Asian populations, a study has found.
Elvira Manzano, 20 Jun 2018
A higher proportion of patients with systemic lupus erythematosus (SLE) experienced improvements in joint and skin symptoms with baricitinib 4 mg once daily vs placebo in a phase II randomized, double-blind, global study.